{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:24:35Z","timestamp":1791908675996,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.semarthrit.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:46:28Z","timestamp":1521420388000},"page":"449-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Statin use and mortality in gout: A general population-based cohort study"],"prefix":"10.1016","volume":"48","author":[{"given":"Sarah F.","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April M.","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2018.03.007_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","article-title":"Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States","volume":"41","author":"Lawrence","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","article-title":"Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout","volume":"73","author":"Perez-Ruiz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-011-0234-2","article-title":"Association between gout and all-cause as well as cardiovascular mortality: a systematic review","volume":"14","author":"Lottmann","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","article-title":"Gout: an independent risk factor for all-cause and cardiovascular mortality","volume":"49","author":"Kuo","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","article-title":"Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans","volume":"67","author":"Singh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case\u2013control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib12","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1681\/ASN.2007111256","article-title":"Association of incident gout and mortality in dialysis patients","volume":"19","author":"Cohen","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.2011.200523","article-title":"Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study","volume":"71","author":"Teng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-209058","article-title":"Improved survival in rheumatoid arthritis: a general population-based cohort study","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib16","first-page":"1383","article-title":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jacc.2003.07.049","article-title":"Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure","volume":"43","author":"Horwich","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCHEARTFAILURE.114.001730","article-title":"Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists' (CTT)","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib23","doi-asserted-by":"crossref","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 2013(1): CD004816.","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib24","first-page":"75","article-title":"A language of health in action: Read Codes, classifications and groupings","author":"Stuart-Buttle","year":"1996","journal-title":"Proc AMIA Annu Fall Symp"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib25","unstructured":"Bank, F.D. Drug Databases\u2014Multilex Drug Data File. Available from: http:\/\/www.fdbhealth.com\/multilex-overview\/."},{"key":"10.1016\/j.semarthrit.2018.03.007_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib27","first-page":"171","article-title":"Feasibility study and methodology to create a quality-evaluated database of primary care data","volume":"12","author":"Bourke","year":"2004","journal-title":"Inform Prim Care"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2125.1997.00647.x","article-title":"Omeprazole, other antiulcer drugs and newly diagnosed gout","volume":"44","author":"Meier","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/pds.1062","article-title":"An application of propensity score matching using claims data","volume":"14","author":"Seeger","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib31","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/annrheumdis-2015-207714","article-title":"Statin use and mortality in rheumatoid arthritis: a general population-based cohort study","volume":"75","author":"Schoenfeld","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib32","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1136\/annrheumdis-2017-211253","article-title":"Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study","volume":"76","author":"Oza","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib33","series-title":"Health and deprivation: inequality and the North","author":"Townsend","year":"1988"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib34","first-page":"318","article-title":"Which deprivation? A comparison of selected deprivation indexes","volume":"13","author":"Morris","year":"1991","journal-title":"J Public Health Med"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jacc.2013.02.098","article-title":"Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm","volume":"62","author":"Sever","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2018.03.007_bib36","doi-asserted-by":"crossref","first-page":"e000046","DOI":"10.1136\/rmdopen-2015-000046","article-title":"Why does the gout attack stop? A roadmap for the immune pathogenesis of gout","volume":"1","author":"Schett","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","article-title":"Synovial fluid analysis for diagnosis of intercritical gout","volume":"131","author":"Pascual","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib39","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcph.146","article-title":"Simvastatin therapy decreases MMP-9 levels in obese women","volume":"53","author":"Andrade","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib40","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.3390\/ijms160511213","article-title":"Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue","volume":"16","author":"Yoshimura","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2261-14-37","article-title":"Simvastatin down-regulates the production of interleukin-8 by neutrophil leukocytes from dyslipidemic patients","volume":"14","author":"Marino","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.intimp.2013.11.003","article-title":"Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia","volume":"18","author":"Pereira","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.21521","article-title":"Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy?","volume":"54","author":"Abeles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib44","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semarthrit.2018.03.007_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3949\/ccjm.82a.14058","article-title":"But how many people died? Health outcomes in perspective","volume":"82","author":"Prasad","year":"2015","journal-title":"Cleve Clin J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217306248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217306248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T22:12:58Z","timestamp":1560377578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217306248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0049017217306248"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin use and mortality in gout: A general population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}